NASDAQ: IKNAIkena Oncology Inc Stock
$1.69+0.03 (+1.81%)
Updated Sep 6, 2024
IKNA Price
$1.69
Fair Value Price
-$0.25
Market Cap
$81.56M
52 Week Low
$1.02
52 Week High
$4.95
P/E
-1.2x
P/B
0.57x
P/S
43.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.84M
Earnings
-$66.71M
Gross Margin
100%
Operating Margin
-3,621.53%
Profit Margin
-3,617.6%
Debt to Equity
0.1
Operating Cash Flow
-$73M
Beta
1.23
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IKNA Overview
Ikena Oncology Incorporated is developing medicines tailored to patient groups with specific unmet needs. Its lead oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional factor in the Hippo signaling pathway. The company is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, IK-175, an oral inhibitor of aryl hydrocarbon receptor, and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. Ikena Oncology was incorporated in 2016 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IKNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IKNA ($1.69) is overvalued by 784.68% relative to our estimate of its Fair Value price of -$0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IKNA ($1.69) is not significantly undervalued (784.68%) relative to our estimate of its Fair Value price of -$0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IKNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IKNA due diligence checks available for Premium users.
Be the first to know about important IKNA news, forecast changes, insider trades & much more!
IKNA News
Valuation
IKNA fair value
Fair Value of IKNA stock based on Discounted Cash Flow (DCF)
Price
$1.69
Fair Value
-$0.25
Undervalued by
784.68%
IKNA ($1.69) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IKNA ($1.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IKNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IKNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.2x
Industry
-46.85x
Market
24.57x
IKNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
6.22x
IKNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IKNA's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.7M
Profit Margin
0%
IKNA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IKNA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$157.5M
Liabilities
$14.6M
Debt to equity
0.1
IKNA's short-term assets ($149.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IKNA's short-term assets ($149.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IKNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.5M
Investing
$3.9M
Financing
$0.0
IKNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IKNA vs Biotech Stocks
Ikena Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.